Literature DB >> 25441311

Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.

Chanjuan Shi1, David S Klimstra2.   

Abstract

Pancreatic neuroendocrine neoplasms include mainly well-differentiated neuroendocrine tumors but also rare poorly differentiated neuroendocrine carcinomas. Molecular mechanisms underlying pancreatic neuroendocrine tumorigenesis have recently been elucidated. While alterations in the chromatin remodeling and PI3K/Akt/mTOR pathways are present in most well-differentiated pancreatic neuroendocrine tumors, mutations in TP53 and RB may contribute to the development of pancreatic poorly differentiated neuroendocrine carcinomas. With these discoveries, new molecular targeted therapies have become available and show promise in some patients with pancreatic well-differentiated neuroendocrine tumor.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetics; Neuroendocrine; Pancreas; Pathology; Tumors

Mesh:

Year:  2014        PMID: 25441311     DOI: 10.1053/j.semdp.2014.08.008

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  11 in total

Review 1.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

2.  EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Authors:  James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

Review 3.  Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; James R Howe
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

4.  Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.

Authors:  Björn Konukiewitz; Anna Melissa Schlitter; Moritz Jesinghaus; Dominik Pfister; Katja Steiger; Angela Segler; Abbas Agaimy; Bence Sipos; Giuseppe Zamboni; Wilko Weichert; Irene Esposito; Nicole Pfarr; Günter Klöppel
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

6.  Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Authors:  Nitya Raj; Emily Valentino; Marinela Capanu; Laura H Tang; Olca Basturk; Brian R Untch; Peter J Allen; David S Klimstra; Diane Reidy-Lagunes
Journal:  Pancreas       Date:  2017-03       Impact factor: 3.327

7.  High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.

Authors:  Bo Zhou; Jie Xiang; Ming Jin; Xiang Zheng; Guogang Li; Sheng Yan
Journal:  BMC Cancer       Date:  2021-03-31       Impact factor: 4.430

8.  A pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) (NET and undifferentiated carcinoma of the pancreas with osteoclast-like giant cells) with metastatic neuroendocrine component to the liver.

Authors:  Guofeng Gao; Amir Qorbani; Chihong Heidi Zhou
Journal:  Autops Case Rep       Date:  2020-12-08

9.  Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology.

Authors:  Xu Han; Xuefeng Xu; Hongyun Ma; Yuan Ji; Dansong Wang; Tiantao Kuang; Wenchuan Wu; Bin Song; Gang Li; Gang Jin; Wenhui Lou
Journal:  Endocr Connect       Date:  2018-02       Impact factor: 3.335

10.  Treatment options for PNET liver metastases: a systematic review.

Authors:  Giuseppe Nigri; Niccolò Petrucciani; Tarek Debs; Livia Maria Mangogna; Anna Crovetto; Giovanni Moschetta; Raffaello Persechino; Paolo Aurello; Giovanni Ramacciato
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.